Monitoring of patients receiving interferon therapy for the treatment of HBV

Assessment point	Laboratory tests
Baseline	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ HBsAg Quantitative HBsAg^Δ INR TSH Creatinine Triglycerides Glucose Pregnancy test^◊
Week 4	CBC with differential Hepatic panel*
Week 12	CBC with differential Hepatic panel* HBV DNA Quantitative HBsAg^Δ TSH Pregnancy test^◊
Week 24	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ TSH Pregnancy test^◊
Week 48	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ HBsAg^§ TSH Pregnancy test^◊
Week 12 post-treatment	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ TSH
Week 24 post-treatment	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ HBsAg^§
Week 36 post-treatment	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ HBsAg^§
Week 48 post-treatment	CBC with differential Hepatic panel* HBV DNA HBeAg and anti-HBe^¶ HBsAg^§

ALT: alanine aminotransferase; AST: aspartate aminotransferase; anti-HBe: hepatitis B e antibody; CBC: complete blood count; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; INR: international normalized ratio; TSH: thyroid stimulating hormone.
* Hepatic panel includes: ALT, AST, albumin, bilirubin, and alkaline phosphatase.
¶ Only for patients who are HBeAg-positive at baseline.
Δ If available to assess utility of continued therapy.
◊ Only for women of childbearing age.
§ Only for HBeAg-negative patients if HBV DNA is undetectable and for HBeAg-positive patients who have undergone HBeAg seroconversion.

Adapted from: Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis 2016 (in press).

Graphic 109129 Version 2.0

خرید پکیج

Monitoring of patients receiving interferon therapy for the treatment of HBV